A promising choice in hypertension treatment: Fixed-dose combinations

Asian Journal of Pharmaceutical Sciences

Volumn 9, Issue 1, 2014, Pages 1-7

  Wan, Xinhuan ^a   Ma, Panqin ^b   Zhang, Xiangrong ^a  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

^b Ningxia Kangya Pharmaceutical Co Ltd   (China)

Author keywords

Fixed dose combination; Hypertension therapy; Monotherapy

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; THIAZIDE DIURETIC AGENT;

ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); DRUG CONTRAINDICATION; DRUG COST; DRUG DOSE REGIMEN; DRUG EFFICACY; HUMAN; HYPERTENSION; MEDICATION COMPLIANCE; META ANALYSIS (TOPIC); MONOTHERAPY; REVIEW;

EID: 84926060527     PISSN: 18180876     EISSN: 2221285X     Source Type: Journal    
DOI: 10.1016/j.ajps.2013.12.005     Document Type: Review

References (29)

1. Clara K., Koon K., Rangarajan S. Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. J Am Med Assoc 2013, 310(9):959-996.
2. Go Alan S., Mozaffarian Dariush, Roger Véronique L. Heart disease and stroke statistics - 2013 update. Circulation 2013, 127:e6-e245.
3. Kearney P.M., Whelton M., Reynolds K., et al. Global burden of hypertension: analysis of worldwide data. Lancet 2005, 365:217-223.
4. Anonymous 1999 World Health Organization - International Society of Hypertension guidelines for the management of hypertension. Guidelines Sub-Committee. J Hypertens 1999, 17:151-183.
5. Girerd X., Hanon O., Pannier B. Trends in the use of antihypertensive drugs in France from 2002 to 2012: FLAHS surveys. Ann Cardiol Angéiol 2013, 62:210-214.
6. Fagan T.C. Remembering the lessons of basic pharmacology. Arch Intern Med 1994, 154:1430-1431.
7. Stanton T., Reid J.L. Fixed dose combination therapy in the treatment of hypertension. J Hum Hypertens 2002, 16:75-78.
8. Reasner C., Olansky L., Seck T.L., et al. The effect of initial therapy with the fixed-dose combination of sitagliptin and metformin compared with metformin monotherapy in patients with type 2 diabetes mellitus. Diabetes Obes Metab 2011, 13(7):644-652.
9. Waeber B., Ruilope L.M. Amlodipine and valsartan as components of a rational and effective fixed-dose combination. Vasc Health Risk Manag 2009, 5:165-174.
10. Weir M.R., Hsueh W.A., Nesbitt S.D., et al. A titrate-to-goal study of switching patients uncontrolled on antihypertensive monotherapy to fixed-dose combinations of amlodipine and olmesartan medoxomil±hydrochlorothiazide. J Clin Hypertens (Greenwich) 2011, 13:404-412.
11. Gupta A.K., Arshad S., Poulter N.R. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension 2010, 55:399-407.
12. Stankus V., Hemmelgarn B., Campbell N., et al. Reducing costs and improving hypertension management. Can J Clin Pharmacol 2009, 16(1):151-155.
13. Okpechi I.G., Schoeman H.S., Longo-Mbenza B., et al. Achieving blood pressure goals study in uncontrolled hypertensive patients treated with a fixed-dose combination of ramipril/hydrochlorothiazide: the astral study. Cardiovasc J Afr 2011, 22(2):79-84.
14. Maeda K., Adachi M., Kinoshita A. Efficacy and safety of the losartan-hydrochlorothiazide combination tablet in patients with hypertension uncontrolled by angiotensin II receptor antagonist therapy: the Aichi Research on Combination therapy for Hypertension (ARCH) study. Intern Med 2012, 51:1167-1175.
15. Mugellini A., Nieswandt V. Candesartan plus hydrochlorothiazide: an overview of its use and efficacy. Expert Opin Pharmacother 2012, 13:2699-2709.
16. Marazzi G., Volterrani M., Caminiti G., et al. Effectiveness of nebivolol and hydrochlorothiazide association on blood pressure, glucose, and lipid metabolism in hypertensive patients. Adv Ther 2010, 27:655-664.
17. Macgregor G.A., Markandu N.D., Banks R.A. Captopril in essential hypertension; contrasting effects of adding hydrochlorothiazide or propranolol. Br Med J 1982, 284:693-696.
18. Sever Peter S., Messerli Franz H. Hypertension management 2011: optimal combination therapy. Eur Heart J 2011, 32:2499-2506.
19. Egan C.G., Pontremoli R. Role of the fixed-dose combination lercanidipine-enalapril in renal protection. J Nephrol 2011, 24:428-437.
20. Sharma S.K., Ruggenenti P., Remuzzi G. Managing hypertension in diabetic patients - focus on trandolapril/verapamil combination. Vasc Health Risk Manag 2007, 3:453-465.
21. Bramlage P., Wolf W.P., Stuhr T., et al. Effectiveness and tolerability of a fixed-dose combination of olmesartan and amlodipine in clinical practice. Vasc Health Risk Manag 2010, 6:803-811.
22. Flack J.M., Calhoun D.A., Satlin L., et al. Efficacy and safety of initial combination therapy with amlodipine/valsartan compared with amlodipine monotherapy in black patients with stage 2 hypertension: the EX-STAND study. J Hum Hypertens 2009, 23:479-489.
23. Hsueh W.A., Shojaee A., Maa J.F., et al. Efficacy of amlodipine/olmesartan medoxomil±HCTZ in obese patients uncontrolled on antihypertensive monotherapy. Curr Med Res Opin 2012, 28:1809-1818.
24. Panjabi S., Lacey M., Bancroft T. Treatment adherence, clinical outcomes, and economics of triple-drug therapy in hypertensive patients. J Am Soc Hypertens 2013, 7(1):46-60.
25. Luo Y., Zu Y., Ahmad S. Challenges of fixed dose combination product development. Am Pharm Rev 2007, 10:120-126.
26. Pudipeddi M. Biopharmaceutical challenges in development of fixed-dose combination. Eastern Pharmaceutical Technology Meeting. Somerset, New Jersey, USA 2010.
27. Taddei S. Fixed-dose combination therapy in hypertension. High Blood Press Cardiovasc Prev 2012, 19(2):55-57.
28. Gorostidi M., Sierra A. Combination therapy in hypertension. Adv Ther 2013, 30:320-336.
29. Epstein Benjamin J., Shah Niren K., Borja-Hart Nancy L. Management of hypertension with fixed-dose triple-combination treatments. Ther Adv Cardiovasc Dis 2013, 7:246-259.